Romosozumab for the treatment of osteoporosis
Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediato...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-03-01
|
| Series: | Osteoporosis and Sarcopenia |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405525518300062 |
| _version_ | 1811253428361363456 |
|---|---|
| author | Michael R. McClung |
| author_facet | Michael R. McClung |
| author_sort | Michael R. McClung |
| collection | DOAJ |
| description | Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediator of osteoblastic activity and bone formation, provided the platform for the evaluation of inhibitors of sclerostin to activate bone formation. An extensive preclinical program and 2 large fracture endpoint trials with romosozumab, a sclerostin-binding antibody, have been completed. This review will highlight the results of those studies and describe the current status of romosozumab as a potential therapy for osteoporosis. Keywords: Romosozumab, Sclerostin, Osteoporosis, Fracture risk, Manuscript category |
| first_indexed | 2024-04-12T16:50:43Z |
| format | Article |
| id | doaj.art-54fbb6e0351949f0ace861e8142f8969 |
| institution | Directory Open Access Journal |
| issn | 2405-5255 |
| language | English |
| last_indexed | 2024-04-12T16:50:43Z |
| publishDate | 2018-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Osteoporosis and Sarcopenia |
| spelling | doaj.art-54fbb6e0351949f0ace861e8142f89692022-12-22T03:24:24ZengElsevierOsteoporosis and Sarcopenia2405-52552018-03-01411115Romosozumab for the treatment of osteoporosisMichael R. McClung0Oregon Osteoporosis Center, 2881 NW Cumberland Road, Portland, OR, 97210, USA.; Oregon Osteoporosis Center, Portland, OR, USARomosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediator of osteoblastic activity and bone formation, provided the platform for the evaluation of inhibitors of sclerostin to activate bone formation. An extensive preclinical program and 2 large fracture endpoint trials with romosozumab, a sclerostin-binding antibody, have been completed. This review will highlight the results of those studies and describe the current status of romosozumab as a potential therapy for osteoporosis. Keywords: Romosozumab, Sclerostin, Osteoporosis, Fracture risk, Manuscript categoryhttp://www.sciencedirect.com/science/article/pii/S2405525518300062 |
| spellingShingle | Michael R. McClung Romosozumab for the treatment of osteoporosis Osteoporosis and Sarcopenia |
| title | Romosozumab for the treatment of osteoporosis |
| title_full | Romosozumab for the treatment of osteoporosis |
| title_fullStr | Romosozumab for the treatment of osteoporosis |
| title_full_unstemmed | Romosozumab for the treatment of osteoporosis |
| title_short | Romosozumab for the treatment of osteoporosis |
| title_sort | romosozumab for the treatment of osteoporosis |
| url | http://www.sciencedirect.com/science/article/pii/S2405525518300062 |
| work_keys_str_mv | AT michaelrmcclung romosozumabforthetreatmentofosteoporosis |